Skip to main content
Premium Trial:

Request an Annual Quote

New Products: InVitae's Hereditary Pancreatic Cancer Test; Enzymatics' Archer FusionPlex; More

Premium

InVitae has launched a hereditary pancreatic cancer panel that covers 17 genes related to pancreatic cancer and the option of adding two genes related to hereditary pancreatitis. The test costs $1,500 in the US and has a turnaround time of three weeks.


Enzymatics has updated its Archer FusionPlex ALK, RET, ROS1 Panel to now include select point mutations in ALK and RET that confer resistance to crizotinib.


MolecularMD, in collaboration with OncoMed, is developing a Notch1 next-generation sequencing-based test. The Notch1 NGS Assay is being developed as a companion diagnostic to identify patients whose cancer may be more likely to benefit from OncoMed's anti-Notch1 antibody, OMP-52M51.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.